Products for Research Use Only

(E/Z) -IT-603

CAT: 0804-HY-121508-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-121508-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(E/Z) -IT-603 is a mixture of E-IT-603 and Z-IT-603 (IT-603) . (E/Z) -IT-603 is also an IĸBα/c-Rel inhibitor. IT-603 is a c-Rel inhibitor with an IC50 of 3 μM. IT-603 has anti-tumor activity. (E/Z) -IT-603 is a promising modulator of T-cell responses in the context of graft-versus-host disease (GVHD) and malignant diseases[1].
CAS Number
292168-90-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
NF-κB
Type
Reference compound
Related Pathways
NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/e-z-it-603.html
Purity
99.91
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(/C(N1)=C\C2=CC(Br)=CC(OC)=C2O)NC1=S
Molecular Formula
C11H9BrN2O3S
Molecular Weight
329.17
Precautions
H302, H315, H319, H335
References & Citations
[1]Yusuke Shono, et al. A small molecule c-Rel inhibitor reduces alloactivation of T-cells without compromising anti-tumor activity. Cancer Discov. 2014 May; 4 (5) : 578-591.|[2]Huang X, et al. ESAT-6 protein suppresses allograft rejection by inducing CD4+Foxp3+ regulatory T cells through IκBα/cRel pathway. Front Immunol. 2025 Jan 9;15:1529226.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported